Naaju Breaking News, Live Updates, Latest Headlines, Viral News, Top Stories, Trending Topics, Videos
[ad_1]
The infectloga Sarah gilbert was in charge of leading a team at the Jenner Institute, University of Oxford, that the genetic sequence of the new coronavirus, began work on a development that could protect against infection.
The doctor has 15 years of experience in the development vaccinations against influenza, and also worked in the fight against MERS, a pathogen in the coronavirus family, which gave it an advantage when spreading covid-19.
AZD1222, commonly known as the ‘Oxford and AstraZeneca vaccine’, is made from a chimpanzee adenovirus (ChAdOx1), to which genetic material has been added so that it can produce the Spike protein (found on the surface of the coronavirus). ) after vaccination and thus prepare the immune system to recognize and attack SARS-CoV-2.
According to the newspaper Clarn, this vaccine This is one of the most advanced: the phase III studies – the last instance before authorization and commercialization – which are carried out in Brazil, South Africa, Great Britain and the United States are already well advanced.
Gilbert gave details on when the new vaccine should be ready for distribution and discussed key information that remains to be learned. After anticipating that a “longer” follow-up will be necessary to see to what extent the immune responses are sustainable.
Regarding the data that is not known, he said that “no one yet knows how strong the antibody response must be to protect against infection or reduce the severity of the disease. That is why we need to. phase III trials to show efficacy data. “.
The infectologist also spoke of the russian vaccine who could reach the Argentina, and felt that “we should find out if the vaccine is working before we start using it outside of clinical trials.”
.
[ad_2]
Source link
